Loading patent…
AssigneeChildren's Hospital of Eastern Ontario Research Institute Inc.
InventorDavid F. STOJDL
Estimating the term…
The present disclosure concerns an oncolytic virus for the treatment of cancer, such as in brain cancer, for example glioblastoma. The oncolytic virus may exhibit reduced levels of neurotoxicity. The oncolytic virus may be an isolated viral particle capable of producing a cDNA polynucleotide that includes a sequence according to SEQ ID NO: 1 when the virus is in a host cell. The oncolytic virus may be an isolated viral particle that includes an RNA polynuclotide that includes a sequence according to SEQ ID NO: 2. The oncolytic virus may be an isolated viral particle having a genome that includes open reading frames that encode: proteins having sequences comprising SEQ ID NOs: 3, 4, 5, 6 and 7; or variants thereof.
A pharmaceutical composition comprising an isolated viral particle having a genome comprising open reading frames that encode:
(canceled)
(canceled)
(canceled)
A pharmaceutical composition comprising an isolated viral particle capable of producing a cDNA polynucleotide when the virus is in a host cell, the cDNA polynucleotide comprising:
(canceled)
(canceled)
A pharmaceutical composition comprising an isolated viral particle capable of producing a cDNA polynucleotide comprising SEQ ID NO:
A pharmaceutical composition comprising an isolated viral particle comprising an RNA polynucleotide comprising SEQ ID NO:
Dependencies are inferred from the claim text.